Alembic Limited (ALEMBICLTD.NS)
INR 145.5
(1.35%)
INR 145.5
(1.35%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 23.28 Billion INR | 5.63% |
| 2022 | 22.04 Billion INR | -16.24% |
| 2021 | 26.31 Billion INR | 9.26% |
| 2020 | 24.08 Billion INR | 63.79% |
| 2019 | 14.7 Billion INR | 16.18% |
| 2018 | 12.65 Billion INR | 9.21% |
| 2017 | 11.59 Billion INR | 16.8% |
| 2016 | 9.92 Billion INR | 23.89% |
| 2015 | 8.01 Billion INR | 124.09% |
| 2014 | 3.57 Billion INR | 0.36% |
| 2013 | 3.56 Billion INR | 3.54% |
| 2012 | 3.43 Billion INR | -67.3% |
| 2011 | 10.51 Billion INR | 210.69% |
| 2010 | 3.38 Billion INR | -66.03% |
| 2009 | 9.96 Billion INR | -1.83% |
| 2008 | 10.15 Billion INR | 7.34% |
| 2007 | 9.45 Billion INR | 6.85% |
| 2006 | 8.85 Billion INR | 29.78% |
| 2005 | 6.82 Billion INR | 9.57% |
| 2004 | 6.22 Billion INR | 11.54% |
| 2003 | 5.58 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 23.28 Billion INR | 5.63% |
| 2023 Q2 | 22.69 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 23.28 Billion INR | 0.0% |
| 2022 Q2 | 25.59 Billion INR | 0.0% |
| 2022 Q4 | 22.04 Billion INR | 0.0% |
| 2022 FY | 22.04 Billion INR | -16.24% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 26.31 Billion INR | 9.26% |
| 2021 Q2 | 26 Billion INR | 0.0% |
| 2021 Q4 | 26.31 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q2 | 19.86 Billion INR | 0.0% |
| 2020 Q4 | 24.08 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 24.08 Billion INR | 63.79% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q2 | 13.8 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 14.7 Billion INR | 0.0% |
| 2019 FY | 14.7 Billion INR | 16.18% |
| 2018 FY | 12.65 Billion INR | 9.21% |
| 2018 Q4 | 12.65 Billion INR | 0.0% |
| 2017 FY | 11.59 Billion INR | 16.8% |
| 2017 Q4 | 11.59 Billion INR | 0.0% |
| 2016 Q4 | 9.92 Billion INR | 0.0% |
| 2016 FY | 9.92 Billion INR | 23.89% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 8.01 Billion INR | 124.09% |
| 2015 Q4 | 8.01 Billion INR | 0.0% |
| 2015 Q2 | 3.69 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q4 | 3.57 Billion INR | 0.0% |
| 2014 FY | 3.57 Billion INR | 0.36% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q2 | 3.67 Billion INR | 0.0% |
| 2013 Q2 | 3.83 Billion INR | 0.0% |
| 2013 Q4 | 3.56 Billion INR | 0.0% |
| 2013 FY | 3.56 Billion INR | 3.54% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2012 FY | 3.43 Billion INR | -67.3% |
| 2012 Q2 | 3.92 Billion INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q4 | 3.43 Billion INR | 0.0% |
| 2011 Q4 | 10.51 Billion INR | 0.0% |
| 2011 FY | 10.51 Billion INR | 210.69% |
| 2010 FY | 3.38 Billion INR | -66.03% |
| 2009 FY | 9.96 Billion INR | -1.83% |
| 2008 Q4 | 10.15 Billion INR | 0.0% |
| 2008 FY | 10.15 Billion INR | 7.34% |
| 2007 FY | 9.45 Billion INR | 6.85% |
| 2006 FY | 8.85 Billion INR | 29.78% |
| 2005 FY | 6.82 Billion INR | 9.57% |
| 2004 FY | 6.22 Billion INR | 11.54% |
| 2003 FY | 5.58 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Sigachi Industries Limited | 6.94 Billion INR | -235.482% |
| Ind-Swift Limited | 6.54 Billion INR | -255.825% |
| Bajaj HealthCare Limited | 7.65 Billion INR | -204.364% |
| Sakar Healthcare Limited | 3.88 Billion INR | -499.181% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 94.833% |
| Innova Captab Limited | 13.2 Billion INR | -76.304% |
| Divi's Laboratories Limited | 154.7 Billion INR | 84.947% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | -116.021% |
| Morepen Laboratories Limited | 12.93 Billion INR | -80.077% |
| Mankind Pharma Limited | 119.63 Billion INR | 80.534% |
| Sequent Scientific Limited | 15.4 Billion INR | -51.181% |
| Wanbury Limited | 3.43 Billion INR | -577.967% |
| Laurus Labs Limited | 83.87 Billion INR | 72.234% |
| Nectar Lifesciences Limited | 21.91 Billion INR | -6.285% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 18.301% |
| Hikal Limited | 24.87 Billion INR | 6.368% |
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 63.87% |
| Neuland Laboratories Limited | 18.32 Billion INR | -27.077% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 41.695% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 83.781% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | -3.759% |
| Themis Medicare Limited | 5.66 Billion INR | -311.141% |
| RPG Life Sciences Limited | 5.12 Billion INR | -354.066% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 92.047% |
| Lupin Limited | 239.97 Billion INR | 90.296% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -534.766% |
| Wockhardt Limited | 76.49 Billion INR | 69.555% |
| Vaishali Pharma Limited | 799.55 Million INR | -2812.575% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 9.811% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -972.78% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 79.835% |
| FDC Limited | 24.68 Billion INR | 5.645% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 93.991% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -870.072% |
| Eris Lifesciences Limited | 70.48 Billion INR | 66.962% |
| Venus Remedies Limited | 6.26 Billion INR | -271.515% |
| ZIM Laboratories Limited | 4.46 Billion INR | -421.185% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | -91.847% |
| Par Drugs and Chemicals Limited | 1.01 Billion INR | -2191.846% |
| Caplin Point Laboratories Limited | 26.97 Billion INR | 13.665% |
| Shilpa Medicare Limited | 30.93 Billion INR | 24.713% |
| Albert David Limited | 4.97 Billion INR | -367.632% |
| Ajanta Pharma Limited | 46.38 Billion INR | 49.794% |
| Hester Biosciences Limited | 6.62 Billion INR | -251.594% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | -3.313% |
| Solara Active Pharma Sciences Limited | 23.46 Billion INR | 0.76% |
| Gufic Biosciences Limited | 10.92 Billion INR | -113.152% |
| Windlas Biotech Limited | 6.26 Billion INR | -271.886% |
| Procter & Gamble Health Limited | 7.94 Billion INR | -193.163% |
| Aarey Drugs & Pharmaceuticals Limited | 3.04 Billion INR | -663.551% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -598.441% |
| Granules India Limited | 55.2 Billion INR | 57.82% |
| Aarti Drugs Limited | 24.32 Billion INR | 4.259% |
| Bal Pharma Limited | 3.2 Billion INR | -626.857% |
| Alkem Laboratories Limited | 155.74 Billion INR | 85.048% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 97.275% |
| Lincoln Pharmaceuticals Limited | 7 Billion INR | -232.543% |
| Medicamen Biotech Limited | 2.94 Billion INR | -690.694% |
| Unichem Laboratories Limited | 31.69 Billion INR | 26.522% |
| Bafna Pharmaceuticals Limited | 1.47 Billion INR | -1476.886% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -4846.127% |
| Valiant Laboratories Limited | 3.42 Billion INR | -579.561% |
| Orchid Pharma Limited | 15.53 Billion INR | -49.869% |
| Medico Remedies Limited | 961.95 Million INR | -2320.877% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | -99.876% |
| Ipca Laboratories Limited | 111.01 Billion INR | 79.023% |
| Brooks Laboratories Limited | 904.45 Million INR | -2474.78% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -475.483% |
| Piramal Enterprises Limited | 826.05 Billion INR | 97.181% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 84.538% |
| NATCO Pharma Limited | 69.06 Billion INR | 66.28% |
| Suven Life Sciences Limited | 2.84 Billion INR | -717.391% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -1207.015% |
| Strides Pharma Science Limited | 58.39 Billion INR | 60.122% |
| Indoco Remedies Limited | 21.44 Billion INR | -8.581% |
| Alpa Laboratories Limited | 1.82 Billion INR | -1175.188% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -1443.574% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -352.153% |